Be the local GP supporting GLP-1 patients in your suburb
The MJA September 2025 consensus sets out FIB-4 calculation, elastography referral, dietitian referral via CDM, and annual metabolic review for every GLP-1 patient. Whether the prescription came from a face-to-face consult or a telehealth platform, the monitoring pathway runs through general practice.
Why this matters now
Almost 500,000 Australians are on GLP-1s. Many were initiated via telehealth and don't have a regular GP for the monitoring pathway. They're searching for one.
The numbers
500K+
Australians on GLP-1s today
JPMorgan Research, Feb 2026
2.5M
projected by 2030
Precedence Research
89%
of eligible patients not yet prescribed
Market analysis
10×
growth in GLP-1 use 2020–2025
Industry data
Data view
The numbers behind the pitch
Australian GLP-1 monthly units — 10× growth since 2020
Source: AIHW + PBS dispensing data analysis
May 2020 → April 2025: ~50K to ~500K units/month — 10× growth in 5 years.
Australian GLP-1 market size — projected to 2034
Source: Precedence Research — Australia GLP-1 RA Market Report, 2024
14.30% CAGR — projected nearly 4× growth in 10 years. Hollow markers = projected.
Australian regulatory timeline — what creates new monitoring requirements
Source: MJA, TGA, PBAC, AASLD official publications
Sep 2025
MJA consensus statement
FIB-4 → elastography mandated for all GLP-1 patients with metabolic risk.
Nov 2025
AASLD practice guidance update
Semaglutide formally recognised as a MASH therapeutic option.
Dec 2025
Wegovy PBS listing recommended
PBAC recommends PBS for established CVD + obesity.
Jan 2026
Mounjaro TGA approval for OSA
Australia's first pharmacological obstructive sleep apnoea treatment.
Mar 2026
Semaglutide patent expires
Generic entry expected to significantly expand patient access.
Apr 2026
Wegovy MASH provisional approval
First GLP-1 liver disease indication in Australia (F2–F3).
The monitoring gap — what telehealth provides vs what guidance requires
Source: MJA 2025; AASLD 2025; Dietitians Australia 2026; TGA PI
| Monitoring need | Telehealth provides? | Clinical guidance |
|---|---|---|
| Prescription + dose schedule | Yes | Standard care |
| Side effect guidance | Yes | Standard care |
| FIB-4 calculation | No | MJA 2025: Required |
| Elastography referral if FIB-4 indeterminate | No | MJA 2025: Required |
| Kidney function monitoring | No | AASLD 2025: Recommended |
| Thyroid monitoring | No | TGA PI: Required |
| Dietitian referral | No | Dietitians Australia 2026 |
| Cardiovascular risk monitoring | No | ADA 2026: Recommended |
| Annual monitoring plan | No | All guidelines: Required |
Clinical context
What the MJA consensus actually requires
The September 2025 MJA consensus statement (doi: 10.5694/mja2.70008) — co-authored by 16 of Australia's leading hepatologists, gastroenterologists, and GPs — mandates that adults with type 2 diabetes, obesity, or two or more metabolic risk factors be tested for MAFLD, and that patients with an indeterminate FIB-4 score (1.3–2.7) undergo second-line liver elastography. Every Australian on a GLP-1 meets at least one of these criteria. Almost none are going through the pathway.
Where the monitoring pathway sits
Most telehealth GLP-1 platforms are designed around streamlined initiation and dose escalation. The MJA consensus pathway — FIB-4 calculation, elastography referral if indeterminate, dietitian referral via CDM plan, kidney function, thyroid, cardiovascular risk review, annual metabolic plan — sits naturally in general practice, regardless of where the script was issued. Patients want a local GP who can run that pathway alongside their prescription.
Why this is the highest-volume opportunity
There are ~500,000 Australians on private GLP-1s today (180,000–240,000 monthly Australian prescriptions per industry data). 89% of eligible patients haven't yet been prescribed. The market is projected to reach 2.5 million Australians by 2030 (Precedence Research). The CDM Plan workflow you already run is exactly what these patients need — and Medicare-funded.
Evidence base
What the literature says, in one place
MJA September 2025 consensus: FIB-4 → elastography pathway mandated for all GLP-1 patients with metabolic risk factors.
MJA 2025, doi: 10.5694/mja2.70008
AASLD updated practice guidance (Nov 2025) formally recognises semaglutide as a MASH therapeutic option.
Wegovy PBS-listed Dec 2025 for established cardiovascular disease + obesity (SELECT trial: 15% MACE reduction, 19% all-cause mortality reduction).
Wegovy provisionally TGA-approved April 2026 for non-cirrhotic MASH with F2–F3 fibrosis — first GLP-1 liver disease approval in Australia.
CDM (Chronic Disease Management) Plan provides Medicare funding for the dietitian + allied health referral chain these patients need.
What your patients are searching
'GLP-1 GP monitoring', 'GP ozempic monitoring', 'finding a GP for fatty liver' are growing queries in every Australian metro. Patients want a local face-to-face GP after a telehealth script.
What a free profile gets you, as a GP
Visible to patients searching 'GLP-1 GP monitoring', 'finding a GP for ozempic' in your suburb.
Free profile lists CDM plan availability, after-hours, and bulk billing.
Optional verified GP badge after AHPRA check.
Built for clinicians, not marketers
We're an Australian-built directory focused on GLP-1 monitoring pathways. No booking fees, no commission, no upsells that gate basic functionality.
Free profile
SEO-optimised profile page that ranks in Google for your suburb + service.
Patient enquiry inbox
Enquiries from patients land in one simple inbox. Respond on your terms.
Demand analytics
See how many patients searched your suburb, viewed your profile, and called.
Verified badge
Once we verify credentials, you get priority placement and a Verified marker.
Claim your free profile in under 5 minutes
No credit card. No lock-in. Visible to patients in your suburb the moment you publish.